Home Duke University Press
QUICK SEARCH:   [advanced]


     
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

First published on October 15, 2008
This version was published on January 1, 2009
Neuro Oncol 2009 11(2):192-200; DOI:10.1215/15228517-2008-086
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
11/2/192    most recent
15228517-2008-086v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pezzolo, A.
Right arrow Articles by Gambini, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Duke University Press

Clinical Investigations

Presence of 1q gain and absence of 7p gain are new predictors of local or metastatic relapse in localized resectable neuroblastoma

Annalisa Pezzolo, Elena Rossi, Stefania Gimelli, Federica Parodi, Francesca Negri, Massimo Conte, Angela Pistorio, Angela Sementa, Vito Pistoia, Orsetta Zuffardi and Claudio Gambini

Departments of Oncology (A.P., F.P., V.P.) and Pathology (F.N., A.S., C.G.), Hematology-Oncology Unit (M.C.), and Epidemiology and Biostatistics Unit (A.P.), IRCCS G. Gaslini Hospital, Genoa; Medical Genetics Department, University of Pavia, Pavia (E.R., S.G., O.Z.); Italy

Address correspondence to Annalisa Pezzolo, IRCCS G. Gaslini Hospital, Largo G. Gaslini, 5, 16147 Genova-Quarto, Italy (annalisapezzolo{at}ospedale-gaslini.ge.it).

We have addressed the search of novel genetic prognostic markers in a selected cohort of patients with stroma-poor localized resectable neuroblastoma (NB) who underwent relapse or progression (group 1) or complete remission (group 2) over a minimum follow-up of 32 months from diagnosis. Twenty-three Italian patients with localized resectable NB (stages 1 and 2) diagnosed from 1994 through 2005 were studied. All patients received surgical treatment. Chemotherapy was administered only to the three stage 2 patients who had MYCN-amplified tumors. High-resolution array-comparative genomic hybridization (CGH) DNA copy-number analysis technology was used to identify novel prognostic markers. Chromosome 1p36.22p36.32 loss and 1q22qter gain, detected almost exclusively in group 1 patients, were significantly associated with poor event-free survival (EFS) (p = 0.0024 and p = 0.024, respectively). In contrast, patients with 7p11.2p22 gain, who belonged predominantly to group 2, had a significantly better EFS (p = 0.015). The frequency of 17q gain or 3p and 11q losses did not differ significantly in group 1 versus group 2 NBs. The sensitive technique allowed us to define the smallest region of 1p deletion. In conclusion, 1q22qter gain and 7p11.2p22 gain might represent new prognostic markers in localized resectable NB, but the small study size and the retrospective nature of the findings warrant further validation of the results in larger studies.

Key Words: 1q gain • 7p gain • array-CGH • localized resectable neuroblastoma • prognostic markers


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents


Copyright 2009 by Society for Neuro-Oncology